PSNL · XBRL financial data

Personalis financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PSNL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	78,648	85,494	65,047	73,481	84,614	69,648
Cost of revenue	58,534	53,837	51,697	55,273	57,789	53,871
Research and development	28,568	49,312	64,912	64,776	48,905	50,264
Selling, general and administrative	33,692	47,698	63,969	49,726	46,187	53,570
Operating income (loss)	(42,146)	(65,353)	(115,531)	(109,936)	(68,267)	(88,057)
Interest income	949	367	2,396	5,901	5,510	7,155
Interest expense	2	184	201	110	24	205
Other income (expense)	(24)	(42)	61	(4,068)	(18,485)	(142)
Income tax expense (benefit)	57	14	40	83	18	21
Net income (loss)	(41,280)	(65,226)	(113,315)	(108,296)	(81,284)	(81,270)
Earnings per share, basic USD per share	(1.20)	(1.49)	(2.48)	(2.25)	(1.37)	(0.91)
Earnings per share, diluted USD per share	(1.20)	(1.49)	(2.48)	(2.25)	(1.37)	(0.91)
Weighted average shares, basic thousands of shares	34,375	43,887	45,705	48,175	59,251	89,240
Weighted average shares, diluted thousands of shares	34,375	43,887	45,705	48,175	59,251	89,240

Fiscal years (PSNL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	68,525	105,585	89,128	56,984	91,415	124,245
Short-term investments	134,765	181,479	78,530	57,195	93,594	115,708
Accounts receivable	6,349	18,468	16,642	17,730	8,140	16,203
Prepaid and other current assets	5,441	7,089	6,808	4,361	3,927	5,651
Total current assets	220,719	318,231	199,699	146,744	203,015	267,951
Property and equipment, net	11,834	19,650	61,935	57,366	48,274	44,815
Right-of-use asset	10,271	53,822	26,480	17,852	16,453	15,118
Total assets	244,842	396,528	292,700	225,099	270,268	334,164
Accounts payable	8,301	9,221	12,854	14,920	6,397	12,989
Accrued liabilities	313	883	1,700	858	—	—
Total current liabilities	40,636	31,313	33,131	47,234	31,126	39,630
Lease liability, non-current	8,541	52,797	41,041	38,321	34,882	31,866
Total liabilities	49,897	86,227	74,561	95,658	67,311	72,979
Accumulated deficit	(181,869)	(247,095)	(360,410)	(468,706)	(549,990)	(631,260)
Total stockholders' equity	194,945	310,301	218,139	129,441	202,957	261,185
Total liabilities and equity	244,842	396,528	292,700	225,099	270,268	334,164
Common shares outstanding (cover page) thousands of shares	43,694	44,950	46,737	50,504	88,263	104,632

Fiscal years (PSNL's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(41,280)	(65,226)	(113,315)	(108,296)	(81,284)	(81,270)
Stock-based compensation	8,238	14,378	19,433	14,051	10,686	9,429
Depreciation and amortization	5,758	6,014	8,432	11,296	10,941	10,046
Net cash from operating activities	(42,653)	(70,828)	(70,233)	(56,258)	(45,150)	(74,946)
Purchases of property and equipment	3,246	11,083	49,896	10,911	1,603	4,504
Net cash from investing activities	(65,143)	(60,069)	52,537	13,099	(35,069)	(22,568)
Proceeds from issuing common stock	117,500	162,258	—	3,513	30,079	126,797
Net cash from financing activities	121,268	169,700	1,366	11,031	114,672	130,338
Net change in cash	13,479	38,850	(16,457)	(32,144)	34,431	32,830

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Personalis	98,271	25,596	(27,072)*	108.4M	6.7 quarters	Q3 FY26 10-QSep 30, 2026
Castle Biosciences	62,116	103,546	15,201*	30.5M	—	Q2 FY26 10-QJun 30, 2026
Celcuity	182,049	not reported	(55,426)*	48.9M	13.6 quarters	Q2 FY26 10-QJun 30, 2026
Fortrea Holdings	220,600	691,500	60,800*	96.5M	—	Q3 FY26 10-QSep 30, 2026
CareDx	250,480	139,362	12,718*	52.5M	—	Q3 FY26 10-QSep 30, 2026
Fulgent Genetics	26,305	85,389	(23,758)*	27.5M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Veracyte	299,521	150,321	45,826*	80.4M	—	Q2 FY26 10-QJun 30, 2026
GRAIL	55,645	44,687	(80,730)*	44.7M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Exagen	24,588	19,941	3,988*	24.2M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.